Latest Health News

Lycopodium Limited reports strong half-year results for 1H FY26, driven by increased project delivery and strategic expansion into the Americas. The company updates its full-year guidance amid a robust pipeline across gold, copper, and critical minerals.

XRF Scientific has reported a record first half for December 2025, with revenue and profits rising on the back of strong mining demand and international expansion.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

SHAPE Australia Corporation Limited has reported a robust first half of FY26, with significant gains in revenue, profits, and project pipeline, underpinned by strategic sector diversification and a key acquisition.

nib Group has announced a 5.47% average increase in health insurance premiums for 2026, citing rising hospital costs and increased claims. The insurer highlights efforts to ease out-of-pocket expenses and support chronic illness management amid sector-wide pressures.

Jayride Group Limited reports a narrower quarterly loss amid revenue challenges, secures $200,000 through convertible notes, and inks a new SaaS agreement with Thailand’s Drivemate to expand its mobility platform.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Viva Leisure has announced a year-long on-market share buy-back program targeting up to 10% of its issued shares, aiming to capitalise on market volatility and reinforce its strong cash flow outlook.

Select Harvests Limited has reported a strong FY2025 financial performance with a net profit after tax of $31.8 million and a significant reduction in net debt. The company plans to resume dividend payments in 2026 amid favourable almond market conditions.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

Aumega Metals has voluntarily suspended its ASX securities as it finalises a capital raising involving a significant new investor. The suspension is expected to last until the capital raising is completed and announced, or until trading resumes on 19 February.

RWC’s H1 FY26 results reveal a 4.6% sales decline and a 22.5% drop in adjusted EBITDA, largely due to US tariffs and regional market pressures. The company is countering challenges by opening a new manufacturing facility in Mexico and expects modest sales recovery in H2 FY26.